UGT1A1 and Hyperbilirubinemia: Increasing evidence has demonstrated that up-regulation of hepatic and intestinal UGT1A1 may accelerate the metabolic clearance of bilirubin or other UGT1A1-substrates, which in turn, provide alternative therapeutic therapy for the treatment of hyperbilirubinaemia and drug-induced liver toxicity (Galijatovic et al., 2001; Sticova and Jirsa, 2013; Goon et al., 2016).